Abstract:4662 In the classical pathway of Nuclear Factor-kappa B (NF-κB) activation, NF-κB subunits are sequestered in the cytoplasm by the Inhibitor of Kappa B (IKB) and released to the nucleus when IKB is phosphorylated by the Inhibitor of Kappa B kinase (IKK) complex. The IKK complex consists of the regulatory IKKγ subunit, along with a dimer of IKKα subunits, IKKβ subunits, or both an IKKα and IKKβ subunit. In this study, our lab showed that IKKα specific induction of NF-κB translocation to the nucleus promoted a pro-angiogenic phenotype in endothelial cells (ECs) in vitro and in vivo through the classical NF-κB signaling pathway. IKKα expression, but not IKKβ expression, increased cell motility and tube formation in endothelial cells (ECs). This pro-angiogenic phenotype could be blocked with the co-expression of IKB, demonstrating that IKKα induction of NF-κB translocation was through the classical pathway. We also found that IKKα activation had a pro-angiogenic effect in vivo. We subcutaneously injected Rag-1 mice with matrigel containing Lewis Lung Carcinoma (LLC) cells alone or LLC cells mixed with either IKKα-expressing or GFP-expressing ECs. Tumor size was measured daily, and tissue was harvested for analysis. We found that LLC cells mixed with IKKα-expressing ECs formed palpable tumors earlier than control tumors and tumors containing IKKα-expressing ECs initially grew much larger than controls. The vascular density was significantly higher, and there were fewer hypoxic regions in tumors containing IKKα-expressing ECs than in control tumors. Tumor cell growth was significantly higher and apoptosis was significantly lower in these tumors compared to control tumors. The data demonstrates that IKKα activation in ECs plays an important role in tumor angiogenesis. IKKα-expressing ECs induced a pro-angiogenic phenotype in ECs in vitro and increased the levels of tumor angiogenesis as demonstrated by an increase vascular density in tumor tissue. The increase in tumor angiogenesis promoted cell growth and lowered the levels of apoptosis in tumor tissue. Thus the expression and activation of IKKα provide potential new targets for anti-angiogenic cancer therapies.

Dysregulation of mTOR pathway by IKKβ links inflammation and tumor angiogenesis

IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis Via the Mtor Pathway

How is the AKT/mTOR Pathway Involved in Cell Migration and Invasion?

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Suppression of Angiogenesis and Tumor Growth by Selective Inhibition of Angiopoietin-2

PKB/Akt-dependent regulation of inflammation in cancer

mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment

Role of IKK-NFκB Signaling Pathway in Inflammation and Tumorigenesis

Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation

Inflammation and tumor progression: signaling pathways and targeted intervention

mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?

Tumor necrosis factor receptor signaling modulates carcinogenesis in a mouse model of breast cancer

MAPK Signaling in Inflammation-Associated Cancer Development

Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer

MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer

Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers

Contemporaneous Inflammatory, Angiogenic, Fibrogenic, and Angiostatic Cytokine Profiles of the Time-to-Tumor Development by Cancer Cells to Orchestrate Tumor Neovascularization, Progression, and Metastasis

STAT3/miR-130b-3p/MBNL1 feedback loop regulated by mTORC1 signaling promotes angiogenesis and tumor growth

Inflammatory Cytokine: An Attractive Target for Cancer Treatment

Macrophage-Induced Tumor Angiogenesis is Regulated by the Tsc2-Mtor Pathway.

Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment